{
    "2018-07-19": [
        [
            {
                "time": "2018-01-03",
                "original_text": "Study Published in The Lancet Shows Benefit of Baricitinib 4 mg for the Treatment of Systemic Lupus Erythematosus (SLE)",
                "features": {
                    "keywords": [
                        "Baricitinib",
                        "Lancet",
                        "Systemic Lupus Erythematosus",
                        "SLE"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-07-25",
                "original_text": "Can Eli Lilly (LLY) Keep the Earnings Streak Alive in Q2?",
                "features": {
                    "keywords": [
                        "Eli Lilly",
                        "LLY",
                        "Earnings Streak",
                        "Q2"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-08-15",
                "original_text": "Pfizer & Lilly's Pain Candidate Succeeds in Phase III Study",
                "features": {
                    "keywords": [
                        "Pfizer",
                        "Lilly",
                        "Phase III",
                        "Pain Candidate"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-09-10",
                "original_text": "LLY vs. NVO: Which Stock Is the Better Value Option?",
                "features": {
                    "keywords": [
                        "LLY",
                        "NVO",
                        "Stock",
                        "Value Option"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-08-20",
                "original_text": "The Zacks Analyst Blog Highlights: Netflix, Eli Lilly, BNY, TJX and Raytheon",
                "features": {
                    "keywords": [
                        "Zacks Analyst Blog",
                        "Netflix",
                        "Eli Lilly",
                        "BNY",
                        "TJX",
                        "Raytheon"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "technology",
                        "financial services",
                        "retail",
                        "defense"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-10-05",
                "original_text": "See what the IHS Markit Score report has to say about Eli Lilly And Co.",
                "features": {
                    "keywords": [
                        "IHS Markit Score",
                        "Eli Lilly",
                        "report"
                    ],
                    "sentiment_score": 0.65,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-11-12",
                "original_text": "Boehringer Ingelheim and Lilly announce Tradjenta's CARMELINA® cardiovascular outcome trial meets primary endpoint",
                "features": {
                    "keywords": [
                        "Boehringer Ingelheim",
                        "Lilly",
                        "Tradjenta",
                        "CARMELINA",
                        "cardiovascular",
                        "outcome trial",
                        "primary endpoint"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-12-01",
                "original_text": "Lilly's Once-Weekly Trulicity® (dulaglutide) Label Updated to Include Data Showing Benefits for Adults with Type 2 Diabetes and Chronic Kidney Disease",
                "features": {
                    "keywords": [
                        "Lilly",
                        "Trulicity",
                        "dulaglutide",
                        "Type 2 Diabetes",
                        "Chronic Kidney Disease"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-11-15",
                "original_text": "Lilly: Tradjenta's CARMELINA Cardiovascular Outcome Trial Meets Primary Endpoint",
                "features": {
                    "keywords": [
                        "Lilly",
                        "Tradjenta",
                        "CARMELINA",
                        "Cardiovascular Outcome Trial",
                        "Primary Endpoint"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            }
        ]
    ]
}